Transarterial Chemoembolization Versus Transarterial Radioembolization in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trial Evidence
Cancers · 18.06.2026 · 18 (12) · 1985
DOI: 10.3390/cancers18121985 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.06.2026. Verfasst von Priyanka Gogna und 8 weiteren Autor:innen. Beteiligte Einrichtung: AstraZeneca, Mississauga, ON L4Y 1M4, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
(1)
Background
This systematic literature review (SLR) and meta-analysis evaluated the comparative clinical effectiveness and safety of transarterial radioembolization (TARE) versus transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). (2)
Methods
Eligible studies were identified through an SLR following PRISMA guidelines using a predefined PICOS framework. PubMed and Embase were searched (2015–2025) for randomized controlled trials (RCTs) and observational studies comparing TARE and TACE. Meta-analyses were conducted for outcomes, including overall survival (OS), objective response rate (ORR), progression-free survival (PFS), and adverse events (AEs). Analyses were conducted for the overall population and predefined subgroups of interest. (3)
Results
Among 1464 studies identified through database searches, 25 studies were selected for meta-analysis comprising 8146 patients with HCC. No significant difference was observed between TARE and TACE in 14 studies evaluating OS (HR: 0.99; 95% CI 0.70–1.39) or 13 studies evaluating ORR (RR: 0.94; 95% CI 0.84–1.05). Four studies reporting meta-analyzable PFS outcomes numerically favored TARE, although the difference was not statistically significant (HR: 0.54; 95% CI 0.29–1.01). Rates of any-grade and grade ≥3 AEs were comparable between the two arms. The results from subgroup analyses remained consistent with the overall findings. (4)
Conclusions
TARE and TACE demonstrate comparable clinical outcomes in patients with HCC. Additional studies within specific, clinically meaningful subgroups of HCC patients will be valuable to further clarify the comparative effectiveness and safety of TARE and TACE in these populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- AstraZeneca, Mississauga, ON L4Y 1M4, Canada.
- AstraZeneca, Gaithersburg, MD 20878, USA.
- Indence Research Private Limited, Kolkata 700156, India.
- AstraZeneca, Cambridge CB2 0AA, UK.
ORCID-Profile: Tushar Pyne, Nilanjan Sinha, Stephen J Valerio
Förderung
- AstraZeneca
Zitieren
APA
Gogna, P., Wang, C., Underwood, D., Farid-Kapadia, M., Dasari, M., Pyne, T., Sinha, N., Stirnadel-Farrant, H. A., & Valerio, S. J. (2026). Transarterial Chemoembolization Versus Transarterial Radioembolization in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trial Evidence. Cancers, 18(12), 1985. https://doi.org/10.3390/cancers18121985
Vancouver
Gogna P, Wang C, Underwood D, Farid-Kapadia M, Dasari M, Pyne T, et al. Transarterial Chemoembolization Versus Transarterial Radioembolization in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trial Evidence. Cancers. 2026;18(12):1985. doi:10.3390/cancers18121985
BibTeX
@article{Gogna2026,
author = {Gogna, Priyanka and Wang, Cindy and Underwood, Dex and Farid-Kapadia, Mufiza and Dasari, Manikanta and Pyne, Tushar and Sinha, Nilanjan and Stirnadel-Farrant, Heide A and Valerio, Stephen J},
title = {Transarterial Chemoembolization Versus Transarterial Radioembolization in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trial Evidence},
journal = {Cancers},
year = {2026},
volume = {18},
number = {12},
pages = {1985},
doi = {10.3390/cancers18121985}
}
EUVIMED